4554 — Fuji Pharma Co Balance Sheet
0.000.00%
- ¥33bn
- ¥60bn
- ¥46bn
- 55
- 83
- 89
- 90
Annual balance sheet for Fuji Pharma Co, fiscal year end - September 30th, JPY millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 12,041 | 10,199 | 3,546 | 2,324 | 4,585 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 11,708 | 11,984 | 12,661 | 16,520 | 18,879 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 34,975 | 34,834 | 34,727 | 39,114 | 42,468 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 12,767 | 14,392 | 18,762 | 20,547 | 20,911 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 61,962 | 64,239 | 75,538 | 85,332 | 90,000 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11,004 | 20,192 | 23,975 | 29,771 | 35,797 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 22,003 | 31,559 | 39,734 | 44,157 | 44,440 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 39,959 | 32,680 | 35,804 | 41,175 | 45,560 |
Total Liabilities & Shareholders' Equity | 61,962 | 64,239 | 75,538 | 85,332 | 90,000 |
Total Common Shares Outstanding |